Free Trial

Best Stocks Under $5 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $5.00 (5 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Aclaris Therapeutics stock logo

1. Aclaris Therapeutics NASDAQ:ACRS

$3.97 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$4.08 +0.12 (+2.90%)
As of 04:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris Therapeutics

Market Capitalization
$555.10 million
Consensus Rating
Buy
Consensus Price Target
$11.00 (+177.1% Upside)
Volume
1.88 million shares
Average Volume
3.88 million shares
Today's Range
$3.87
▼
$4.07
Galiano Gold stock logo

2. Galiano Gold NYSEAMERICAN:GAU

$1.94 0.00 (0.00%)
Closing price 10/30/2026 04:10 PM Eastern
Extended Trading
$1.94 0.00 (0.00%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Galiano Gold Inc engages in the exploration and evaluation of gold properties in Canada. Its flagship asset is the Asanko Gold Mine that covers an area of approximately 21,000 hectares located in Ghana, West Africa. More about Galiano Gold

Market Capitalization
$508.38 million
P/E Ratio
7.46
Consensus Rating
Buy
Consensus Price Target
$3.85 (+98.5% Upside)
Volume
2.83 million shares
Average Volume
2.65 million shares
Cronos Group stock logo

3. Cronos Group NASDAQ:CRON

$3.30 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$3.33 +0.03 (+0.91%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cronos Group Inc operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. More about Cronos Group

Market Capitalization
$1.22 billion
P/E Ratio
16.50
Consensus Rating
Buy
Consensus Price Target
$2.30 (-30.3% Downside)
Volume
1.09 million shares
Average Volume
804,222 shares
Taysha Gene Therapies stock logo

4. Taysha Gene Therapies NASDAQ:TSHA

$4.13 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$4.20 +0.08 (+1.82%)
As of 04:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. More about Taysha Gene Therapies

Market Capitalization
$1.35 billion
Consensus Rating
Buy
Consensus Price Target
$12.77 (+209.2% Upside)
Volume
1.50 million shares
Average Volume
4.13 million shares
Today's Range
$4.07
▼
$4.25
B2Gold stock logo

5. B2Gold NYSEAMERICAN:BTG

$4.60 0.00 (0.00%)
As of 10/30/2026 04:10 PM Eastern

B2Gold Corp. operates as a gold producer company. It operates the Fekola Mine in Mali, the Masbate Mine in the Philippines, and the Otjikoto Mine in Namibia. More about B2Gold

Market Capitalization
$6.06 billion
P/E Ratio
8.36
Consensus Rating
Buy
Consensus Price Target
$6.81 (+48.1% Upside)
Volume
32.19 million shares
Average Volume
20.53 million shares
Lexeo Therapeutics stock logo

6. Lexeo Therapeutics NASDAQ:LXEO

$3.14 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$3.14 +0.00 (+0.16%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. More about Lexeo Therapeutics

Market Capitalization
$257.64 million
Consensus Rating
Buy
Consensus Price Target
$16.43 (+423.2% Upside)
Volume
1.00 million shares
Average Volume
1.45 million shares
Today's Range
$2.90
▼
$3.30
Compugen stock logo

7. Compugen NASDAQ:CGEN

$1.98 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$1.98 +0.00 (+0.05%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. More about Compugen

Market Capitalization
$187.21 million
P/E Ratio
5.21
Consensus Rating
Buy
Consensus Price Target
$5.00 (+152.5% Upside)
Volume
255,448 shares
Average Volume
240,549 shares
Grab stock logo

8. Grab NASDAQ:GRAB

$2.71 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$2.74 +0.04 (+1.29%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grab Holdings Limited engages in the provision of superapps in Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. More about Grab

Market Capitalization
$11.10 billion
P/E Ratio
45.17
Consensus Rating
Buy
Consensus Price Target
$5.91 (+117.9% Upside)
Volume
54.80 million shares
Average Volume
60.07 million shares
Palisade Bio stock logo

9. Palisade Bio NASDAQ:PALI

$1.16 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$1.19 +0.03 (+2.59%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More about Palisade Bio

Market Capitalization
$202.15 million
Consensus Rating
Buy
Consensus Price Target
$9.29 (+700.5% Upside)
Volume
3.09 million shares
Average Volume
2.97 million shares
Today's Range
$1.12
▼
$1.20
iBio stock logo

10. iBio NASDAQ:IBIO

$0.77 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$0.79 +0.02 (+2.77%)
As of 04:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBio

Market Capitalization
$49.44 million
Consensus Rating
Buy
Consensus Price Target
$6.00 (+680.5% Upside)
Volume
213,528 shares
Average Volume
870,968 shares
Today's Range
$0.74
▼
$0.81
Stereotaxis stock logo

11. Stereotaxis NYSEAMERICAN:STXS

$0.86 0.00 (0.00%)
Closing price 10/30/2026 04:10 PM Eastern
Extended Trading
$0.94 +0.08 (+9.55%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about Stereotaxis

Market Capitalization
$86.43 million
Consensus Rating
Buy
Consensus Price Target
$3.50 (+305.8% Upside)
Volume
1.44 million shares
Average Volume
636,491 shares
Today's Range
$0.81
▼
$0.92
Ur Energy stock logo

12. Ur Energy NYSEAMERICAN:URG

$0.85 0.00 (0.00%)
Closing price 10/30/2026 04:10 PM Eastern
Extended Trading
$0.87 +0.02 (+2.14%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization
$339.65 million
Consensus Rating
Buy
Consensus Price Target
$2.23 (+162.2% Upside)
Volume
7.60 million shares
Average Volume
11.67 million shares
Today's Range
$0.84
▼
$0.87
Larimar Therapeutics stock logo

13. Larimar Therapeutics NASDAQ:LRMR

$2.47 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$2.52 +0.04 (+1.82%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. More about Larimar Therapeutics

Market Capitalization
$256.58 million
Consensus Rating
Buy
Consensus Price Target
$10.33 (+318.4% Upside)
Volume
777,218 shares
Average Volume
1.54 million shares
Today's Range
$2.42
▼
$2.66
Niagen Bioscience stock logo

14. Niagen Bioscience NASDAQ:NAGE

$2.33 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$2.35 +0.02 (+0.94%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. More about Niagen Bioscience

Market Capitalization
$185.57 million
P/E Ratio
12.95
Consensus Rating
Buy
Consensus Price Target
$10.33 (+343.5% Upside)
Volume
523,863 shares
Average Volume
495,932 shares
Inventiva stock logo

15. Inventiva NASDAQ:IVA

$3.65 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$3.59 -0.06 (-1.64%)
As of 04:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. More about Inventiva

Market Capitalization
$868.66 million
Consensus Rating
Buy
Consensus Price Target
$15.86 (+334.4% Upside)
Volume
1.73 million shares
Average Volume
2.81 million shares
Today's Range
$3.59
▼
$3.76
Ovid Therapeutics stock logo

16. Ovid Therapeutics NASDAQ:OVID

$2.54 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$2.48 -0.06 (-2.17%)
As of 04:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization
$496.06 million
Consensus Rating
Moderate Buy
Consensus Price Target
$6.00 (+136.2% Upside)
Volume
3.15 million shares
Average Volume
1.86 million shares
Today's Range
$2.44
▼
$2.70
Equillium stock logo

17. Equillium NASDAQ:EQ

$1.37 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$1.36 -0.01 (-0.51%)
As of 04:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More about Equillium

Market Capitalization
$86.87 million
Consensus Rating
Moderate Buy
Consensus Price Target
$7.57 (+452.7% Upside)
Volume
310,608 shares
Average Volume
557,882 shares
Today's Range
$1.29
▼
$1.42
Inhibikase Therapeutics stock logo

18. Inhibikase Therapeutics NASDAQ:IKT

$1.55 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$1.54 -0.01 (-0.32%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase Therapeutics

Market Capitalization
$216.29 million
Consensus Rating
Moderate Buy
Consensus Price Target
$4.75 (+206.5% Upside)
Volume
438,286 shares
Average Volume
688,011 shares
Today's Range
$1.52
▼
$1.67
WAVE Life Sciences stock logo

19. WAVE Life Sciences NASDAQ:WVE

$3.59 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$3.78 +0.19 (+5.26%)
As of 04:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. More about WAVE Life Sciences

Market Capitalization
$708.05 million
Consensus Rating
Moderate Buy
Consensus Price Target
$20.89 (+481.9% Upside)
Volume
3.33 million shares
Average Volume
3.05 million shares
Today's Range
$3.43
▼
$3.70
Prime Medicine stock logo

20. Prime Medicine NASDAQ:PRME

$4.72 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$4.80 +0.08 (+1.78%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. More about Prime Medicine

Market Capitalization
$856.11 million
Consensus Rating
Moderate Buy
Consensus Price Target
$7.47 (+58.3% Upside)
Volume
6.56 million shares
Average Volume
6.45 million shares
Today's Range
$4.68
▼
$5.20
Opus Genetics stock logo

21. Opus Genetics NASDAQ:IRD

$3.67 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$3.64 -0.03 (-0.93%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. More about Opus Genetics

Market Capitalization
$303.32 million
Consensus Rating
Moderate Buy
Consensus Price Target
$12.71 (+246.4% Upside)
Volume
1.02 million shares
Average Volume
1.55 million shares
Today's Range
$3.42
▼
$3.69
Adicet Bio stock logo

22. Adicet Bio NASDAQ:ACET

$3.42 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$3.95 +0.53 (+15.58%)
As of 04:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet Bio

Market Capitalization
$32.01 million
Consensus Rating
Moderate Buy
Consensus Price Target
$37.80 (+1,005.3% Upside)
Volume
242,465 shares
Average Volume
207,625 shares
Today's Range
$3.32
▼
$3.74
Cabaletta Bio stock logo

23. Cabaletta Bio NASDAQ:CABA

$1.51 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$1.45 -0.06 (-3.77%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More about Cabaletta Bio

Market Capitalization
$256.01 million
Consensus Rating
Moderate Buy
Consensus Price Target
$15.60 (+933.1% Upside)
Volume
3.73 million shares
Average Volume
4.89 million shares
Today's Range
$1.43
▼
$1.59
Gold Royalty stock logo

24. Gold Royalty NYSEAMERICAN:GROY

$2.66 0.00 (0.00%)
Closing price 10/30/2026 04:10 PM Eastern
Extended Trading
$2.64 -0.02 (-0.64%)
As of 05:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. More about Gold Royalty

Market Capitalization
$613.96 million
P/E Ratio
266.27
Consensus Rating
Moderate Buy
Consensus Price Target
$5.38 (+102.1% Upside)
Volume
2.19 million shares
Average Volume
1.21 million shares
Tvardi Therapeutics stock logo

25. Tvardi Therapeutics NASDAQ:TVRD

$0.79 0.00 (0.00%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$0.81 +0.02 (+2.17%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. More about Tvardi Therapeutics

Market Capitalization
$10.58 million
Consensus Rating
Moderate Buy
Consensus Price Target
$9.40 (+1,085.7% Upside)
Volume
154,881 shares
Average Volume
128,547 shares
Today's Range
$0.77
▼
$0.93

Frequently Asked Questions

The list features stocks trading at $5 or less that have favorable consensus ratings from Wall Street analysts. It is not a comprehensive list of every stock below that price threshold.

The companies shown can change as share prices fluctuate and analyst recommendations are updated.

No. A stock's share price tells investors how much one share costs, not whether the company is attractively valued. A $3 stock can be expensive relative to its earnings or assets, while a $100 stock can be undervalued.

Market capitalization, earnings, cash flow, debt and growth prospects provide more meaningful context. Investors should also consider why a stock trades at a low price.

A consensus rating summarizes recommendations from analysts who cover a stock. A Buy rating generally indicates favorable analyst sentiment, while Moderate Buy suggests a less strongly positive overall assessment.

Consensus ratings reflect analysts' opinions rather than guarantees of future performance. The number of analysts covering a company also matters, since a rating based on only a few recommendations may be less informative than one supported by broader coverage.

A large gap between a stock's current price and its consensus price target can produce an unusually high upside percentage. This may occur when a company's share price has fallen sharply or analysts have not yet revised their targets to reflect changing circumstances.

Large projected gains should not be interpreted as more likely gains. Investors should examine how recently analysts updated their targets, how many analysts contribute to the consensus and whether the company's financial outlook supports those expectations.

Start with the company's financial condition, including revenue, profitability, cash reserves, debt and cash flow. For businesses that are not profitable, consider how long existing cash could support operations and whether additional financing might dilute current shareholders.

Investors should also review trading liquidity, recent SEC filings, business risks and the reasons behind analysts' recommendations. Low-priced stocks can experience substantial volatility, and some may be difficult to sell without affecting the market price.